These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Dowling P, Meleady P, O'Driscoll L, Watson W, O'Connor R. Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417 [Abstract] [Full Text] [Related]
29. A small molecule induces integrin β4 nuclear translocation and apoptosis selectively in cancer cells with high expression of integrin β4. Liu SY, Ge D, Chen LN, Zhao J, Su L, Zhang SL, Miao JY, Zhao BX. Oncotarget; 2016 Mar 29; 7(13):16282-96. PubMed ID: 26918348 [Abstract] [Full Text] [Related]
34. Prostate field cancerization and exosomes: Association between CD9, early growth response 1 and fatty acid synthase. Amirrad F, Pytak PA, Sadeghiani-Pelar N, Nguyen JPT, Cauble EL, Jones AC, Bisoffi M. Int J Oncol; 2020 Apr 29; 56(4):957-968. PubMed ID: 32319557 [Abstract] [Full Text] [Related]
36. Identification of prostate cancer biomarkers in urinary exosomes. Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K, Llorente A. Oncotarget; 2015 Oct 06; 6(30):30357-76. PubMed ID: 26196085 [Abstract] [Full Text] [Related]
37. Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo. Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H, Wicklein D, Gebauer F, Bröker K, Stürken C, Milde-Langosch K, Oliveira-Ferrer L, Ricklefs FL, Ewald F, Wolters-Eisfeld G, Riecken K, Unrau L, Krause L, Bohnenberger H, Offermann A, Perner S, Sebens S, Lamszus K, Diehl L, Linder S, Jücker M, Schumacher U, Lange T. J Hematol Oncol; 2023 Mar 17; 16(1):23. PubMed ID: 36932441 [Abstract] [Full Text] [Related]
38. Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration. Ai J, Jin T, Yang L, Wei Q, Yang Y, Li H, Zhu Y. Oncotarget; 2017 Oct 10; 8(47):82430-82436. PubMed ID: 29137275 [Abstract] [Full Text] [Related]
39. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS. Proteomics; 2014 Mar 10; 14(6):699-712. PubMed ID: 24376083 [Abstract] [Full Text] [Related]
40. Cancer Exosomes as Mediators of Drug Resistance. André Mdo R, Pedro A, Lyden D. Methods Mol Biol; 2016 Mar 10; 1395():229-39. PubMed ID: 26910077 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]